EDMONTON, AB, March
20, 2024 – PRESS RELEASE – Aurora Cannabis Inc., a Canadian-based
leading global medical cannabis company, has received Good Manufacturing
Practice (GMP) certification from Australia's Therapeutic Goods Administration
(TGA) for its Canadian production facilities, River and Ridge. The TGA is
responsible for regulating the supply, import, export, manufacturing and
advertising of therapeutic goods in Australia.
Obtaining
TGA's GMP certification enables the company to deliver top-tier cannabis
products to Australia while confirming Aurora's dedication to exporting
products fully compliant with TGA regulations and the stipulations of TGO 93
(Standard for Medical Cannabis). The license grants approval for Aurora to
broaden its product range offerings in the country, comprising dried flower,
resin cartridges, pastilles and oils.
"I'm
proud to announce Aurora has obtained TGA GMP certification for our world class
Canadian production facilities," said Gorana Lakic, vice president of quality
at Aurora. "This achievement adds to the number of global certifications
Aurora has received and solidifies our dedication to quality and compliance.
With this significant achievement, we reaffirm our commitment to maintaining
the highest standards and manufacturing practices to deliver premium medical
cannabis products to our valued patients."
This
landmark certification, granted on March 15, 2024, strengthens Aurora's
dedication to supporting the continued growth and development of the Australian
medical cannabis market, which is rapidly expanding and estimated to be worth
$400 million AUD, making it the largest medical market in the world outside of
North America. As the long-standing exclusive supplier to MedReleaf
Australia, and recently announced parent company, Aurora will continue to
introduce innovative and differentiated products to the market.
MedReleaf
Australia and Aurora remain dedicated to ensuring Australian patients can
access a dependable and consistent supply of premium-quality products and
providing doctors expanded options for patient care.
For
further information about medical cannabis products, doctors and health care
professionals can contact MedReleaf Australia's clinical support team or visit its
website: www.medreleafaustralia.com.au.
Latest from Cannabis Business Times
- USC Athletics, Cookies Announce Trailblazing CBD Partnership for College Football, Basketball Sponsorship
- Trulieve Set to Open Medical Cannabis Dispensary in Clearwater
- Kentucky’s Medical Cannabis Program Attracts 5K License Applicants
- AYR Wellness Awarded Virginia’s HSA I Vertical Cannabis License
- Navigating the Green Line: How to Balance Selling and Profitability in Cannabis Retail
- DCC’s ‘Inadequate Oversight’ of $100M Undermined California Licensing Program for Cannabis Growers
- High Tide to Open Canna Cabana Store in Lucan, Ontario
- Whitney Economics Reduces 2030 Hemp Fiber and Grain Acreage Forecast by 4.5 Million Acres